SYPL2 Antibody
| Code | Size | Price |
|---|
| PSI-5255-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5255-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
SYPL2 Antibody: MG29, Synaptophysin-like protein 2
Application Note:
SYPL2 antibody can be used for detection of SYPL2 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
SYPL2 Antibody: SYPL2, also known as Mitsugumin 29, was initially identified as a transmembrane protein from the triad junction in skeletal muscle that had significant homology with members of the synaptophysin family. SYPL2 is thought to participate in the excitation-contraction coupling process of skeletal muscle as SYPL2-null mice showed reduced muscle contractile force and altered triad junction structure and increased susceptibility to fatigue of the skeletal muscle. SYPL2 plays a critical role in muscle Ca2+ signaling by regulating the process of store-operated Ca2+ entry and interacts with ryanodine receptor (RyR), thereby influencing intracellular Ca2+ homeostasis through changes in the RyR/Ca2+ release function. Co-expression of SYPL2 and RyR in cultured cells leads to apoptotic cell death resulting from the depletion of Ca2+ from the intracellular stores.
Background References:
- Takeshima H, Simuta M, Komazaki S, et al. Mitsugumin29, a novel synaptophysin family member from the triad junction in skeletal muscle. Biochem. J.1998; 331:317-22.
- Nishi M, Komazaki S, Kurebayashi Y, et al. Abnormal features in skeletal muscle from mice lacking mitsugumin29. J. Cell Biol.1999; 147:1473-80.
- Nagaraj RY, Nosek CM, Brotto MA, et al. Increased susceptibility to fatigue of slow- and fast-twitch muscles from mice lacking the MG29 gene. Physiol. Genom.2000; 4:43-9.
- Pan Z, Hirata D, Nagaraj RY, et al. Dysfunction of store-operated calcium channel in muscle cells lacking mg29. Nat. Cell Biol.2002; 4:379-83.
Buffer:
SYPL2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rabbit: (100%)
Immunogen:
SYPL2 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human SYPL.
The immunogen is located within the last 50 amino acids of SYPL2.
The immunogen is located within the last 50 amino acids of SYPL2.
NCBI Gene ID #:
284612
NCBI Official Name:
synaptophysin-like 2
NCBI Official Symbol:
SYPL2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_001035799
Protein GI Number:
105554421
Purification:
SYPL2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
SPECIFICITY:
At least two isoforms of SYPL2 are known to exist. SYPL2 antibody will not cross-react with SYPL1.
Swissprot #:
Q5VXT5
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | SYPL2 Peptide | PSI-5255P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|